Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Yijue Xue"'
Autor:
Min Wang, Jiannan Liu, Xingming Liao, Yasong Yi, Yijue Xue, Ling Yang, Hailing Cheng, Pixu Liu
Publikováno v:
Redox Biology, Vol 67, Iss , Pp 102931- (2023)
Cancer cells frequently exhibit aberrant redox homeostasis and adaptation to oxidative stress. Hence abrogation of redox adaptation in cancer cells can be exploited for therapeutic benefit. Here we report SGK3 functions as an anti-oxidative factor to
Externí odkaz:
https://doaj.org/article/ae745aed3646417c8644e9b3c4873c93
Autor:
Jingyan Yi, Chongya Liu, Zhiwei Tao, Min Wang, Yaxun Jia, Xiaolin Sang, Lanlin Shen, Yijue Xue, Kui Jiang, Fuwen Luo, Pixu Liu, Hailing Cheng
Publikováno v:
EBioMedicine, Vol 43, Iss , Pp 225-237 (2019)
Background: While PARP inhibitors and CDK4/6 inhibitors, the two classes of FDA-approved agents, have shown promising clinical benefits, there is an urgent need to develop new therapeutic strategies to improve clinical response. Meanwhile, extending
Externí odkaz:
https://doaj.org/article/f53d36afe16b4bcb8a9eaaa5adf3f8dc
Autor:
Min Wang, Yijue Xue, Lanlin Shen, Pan Qin, Xiaolin Sang, Zhiwei Tao, Jingyan Yi, Jia Wang, Pixu Liu, Hailing Cheng
Publikováno v:
Redox Biology, Vol 24, Iss , Pp - (2019)
Cervical cancer has poor prognosis and patients are often diagnosed at advanced stages of the disease with limited treatment options. There is thus an urgent need for the discovery of new therapeutic strategies in cervical cancer. The activation of S
Externí odkaz:
https://doaj.org/article/e107407b6ac34ff69b8bfcccacf130b7
Autor:
Hailing Cheng, Yijue Xue, Fuwen Luo, Kui Jiang, Pixu Liu, Lanlin Shen, Yaxun Jia, Xiaolin Sang, Chongya Liu, Zhiwei Tao, Min Wang, Jingyan Yi
Publikováno v:
EBioMedicine. 43:225-237
Background While PARP inhibitors and CDK4/6 inhibitors, the two classes of FDA-approved agents, have shown promising clinical benefits, there is an urgent need to develop new therapeutic strategies to improve clinical response. Meanwhile, extending t
Autor:
Wenzhi Zhao, Yuan Zhang, Hailing Cheng, Pixu Liu, Xiaolin Sang, Fuwen Luo, Chongya Liu, Lanlin Shen, Nan Zhang, Xiaonan Wang, Zundong Liu, Yijue Xue, Jinlei Ding, Min Wang, Jingyan Yi
Publikováno v:
Cancer Letters. :54-63
Selective phosphatidylinositol 3 kinase (PI3K) inhibitors are being actively tested in clinical trials for ERα-positive (ER+) breast cancer due to the presence of activating PIK3CA mutations. However, recent studies have revealed that increased ERα
Autor:
Zhen Xiao, Pixu Liu, Yijue Xue, Hong Shi, Yingying He, Chongya Liu, Lin Xiang, Tingting Shen, Lanlin Shen, Min Wang, Jingyan Yi
Publikováno v:
Oncology Reports
Uterine serous carcinoma (USC) is a subtype of endometrial cancer. Compared with endometrial endometroid carcinoma, the majority of USC cases are more aggressive. Cyclin-dependent kinase inhibitor 2A (P16INK4A) is a canonical tumor suppressor that bl
Autor:
Zhiwei Tao, Pan Qin, Hailing Cheng, Min Wang, Jingyan Yi, Xiaolin Sang, Jia Wang, Lanlin Shen, Yijue Xue, Pixu Liu
Publikováno v:
Redox Biology, Vol 24, Iss, Pp-(2019)
Cervical cancer has poor prognosis and patients are often diagnosed at advanced stages of the disease with limited treatment options. There is thus an urgent need for the discovery of new therapeutic strategies in cervical cancer. The activation of S